Corporate Profile

Contact Information
Nancy Broadbent
CollaGenex
215-579-7388

Evan Smith, CFA or Erica Pettit
Financial Dynamics
212-850-5606 or 212 850-5614

Stock Information

Symbol	CGPI
Year End	December
Headquarters	Newtown, PA
Website	www.collagenex.com
Stock Price (as of 11/30/05)	$9.56
52-Week Range	$3.76 - $10.80
Market Cap.	$139m
Shares Out. (Fully Diluted)	14.4m

FY05 Guidance (as of 11/03/05)

Total Revenues:	~$26 million
R&D Expense:	~$15 million
SG&A Expense, including restructuring costs:	~$27 million
Net Loss allocable to common stockholders (per basic and diluted share):	($1.48)-($1.50)
Cash Burn:	~$12 million
Cash and Short Term Investments (at December 31, 2005):	~$27 million

Analyst Coverage

Friedman, Billings, Ramsey	Robert Uhl
McGinn Smith	Michael Boylan
Natexis Bleichroeder	Timothy Chiang
RBC Capital Markets	Ken Trbovich
Rodman & Renshaw	Ren Benjamin
Roth Capital	Mark Taylor
SunTrust Robinson Humphrey	Robert Hazlett

Investment Highlights

- Experienced management team with proven record of building pharmaceutical brands
- Targeting $2.7 billion segment of dermatology market
- Lead product OraceaTM offers significant near-term opportunity
- Highly favorable Phase III results NDA submission Q3/05
- Two proprietary technologies fueling robust product pipeline

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company that has built its reputation on providing innovative medical therapies to the dental and dermatology markets.

CollaGenex's professional dermatology sales force markets Pandel®, a prescription topical corticosteroid licensed from Altana, Inc., Alcortin™ (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort™ (2% hydrocortisone acetate and 1% pramoxine HCl). Alcortin and Novacort are marketed by the Company under an agreement with Primus Pharmaceuticals Inc. CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues and by enhancing bone protein synthesis, and Atridox®, Atrisorb FreeFlow® and Atrisorb-D FreeFlow®, which are products of QTL, Inc., the successor to Atrix Laboratories, Inc., for the treatment of adult periodontitis.

Research has shown that certain tetracyclines can be chemically modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body's connective tissues. CollaGenex is evaluating various chemically modified tetracyclines (so called “IMPACS” compounds because they are Inhibitors of Multiple Proteases And CytokineS) to assess whether they are safe and effective in these applications. The Company has a pipeline of innovative product candidates with possible applications in dermatology and other disease states. In addition, CollaGenex has acquired the Restoraderm technology, a unique, proprietary dermal drug delivery system, and plans to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties.

CollaGenex Pharmaceuticals

Strategic Plan for Growth

- Proven capability to develop winning products
  - Developed Periostat® for adult periodontitis – most successful pharmaceutical brand in dental market
  - Oracea® poised to enter $500M rosacea market
- Targeting $5.8B dermatology market
  - 47% of market, or $2.7B, served by CGPI's product pipeline
- Strong technology platforms
  - IMPACS® - Broad range of anti-inflammatory activities
  - Restoraderm - Unique topical foam delivery technology
- Strong intellectual property position
  - 30 issued, 5 pending U.S. patents covering IMPACS® to provide multiple protections for selected compounds and indications
- Established infrastructure in dermatology
  - Highly-trained 34-person sales force is targeting 5,600 dermatologists, who generate 85% of rosacea prescriptions
  - Sales force developing relationships with dermatologists by marketing three products

Oracea: The Lead Product

- **Market:** Disease characterized by inflammatory lesions, erythema (an episodic skin redness), and telangiectasia (spider veins)
- **Existing Products:** Currently only topical anti-infectives have rosacea label so there may be a significant opportunity to expand current $500M market with first FDA-approved systemic treatment
- **Clinical Results:** Completed largest clinical trial ever to evaluate systemic therapy for rosacea with two double-blinded, placebo-controlled clinical trials enrolled total of 537 patients in 28 centers across U.S. for a 16-week administration, 4-week follow-up
  - Primary endpoint: reduction in inflammatory lesions
    Highly significant clinical and statistical results: In the two studies, patients receiving Oracea experienced a 61% and 46% mean reduction in inflammatory lesions compared to 29% and 20%, respectively, in patients receiving placebo.

Advanced Pipeline of Innovative Products

		Preclinical	Phase I	Phase II	Phase III	Approved & Marketed	Phase IV
Dermatology							
Pandel	Dermatoses	●	●	●	●	●	
Oracea	Rosacea	●	●	●	●	2006	
Restoraderm	Acne	●	●	●		2005	
Restoraderm	Psoriasis	●				2008	
COL-3	Acne	●	●	●			
Dental							
Periostat	Peridontitis	●	●	●	●	●	●
Other							
COL-308	TBD	●					
COL-1002	TBD	●					

2005 Milestones

	H1 2005	H2 2005	H1 2006	H2 2006
Complete Col-3 Rosacea pilot study	●			
Complete Oracea Phase III studies	●			
Submit Oracea NDA	●	●		
Report allowance of acne/rosacea patent	●	●		
Begin Phase II study of Col-3 in acne		●	●	
Launch Restoraderm product for acne	●	●		
Initiate sales force expansion	●	●		
Acquire/in-license product(s) to complete portfolio	●	●	●	●

Forward-Looking Statements

This document contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Investors are cautioned that forward-looking statements involve risks and uncertainties, which may affect the Company's business and prospects. The Company's business of selling, marketing and developing pharmaceutical products is subject to a number of significant risks, including risks relating to the implementation of the Company's sales and marketing plans for products that the Company markets, risks inherent in research and development activities, risks associated with conducting business in a highly regulated environment and uncertainty relating to clinical trials of products under development, all as discussed in the Company's periodic filings with the U.S. Securities and Exchange Commission.